Stock Market Reviews

BLCO (Bausch + Lomb Corporation) News

Get the latest news, insights, and market updates on BLCO (Bausch + Lomb Corporation). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Integra LifeSciences, GE HealthCare, Bausch + Lomb, ICU Medical, and Universal Health Services Shares Are Falling, What You Need To Know
  A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the healthcare industry showing significant job losses.
  Mar 6, 2026 - $BLCO
• 2 Profitable Stocks Worth Investigating and 1 We Ignore
  Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
  Mar 5, 2026 - $BLCO
• Toymaker Hasbro joins wave of companies suing U.S. government over IEEPA tariff payments
  NEW YORK, NY, Feb 27 - Toymaker Hasbro on Friday joined ‌hundreds of companies suing for refunds ‌of tariffs paid under President Donald Trump’s emergency ​trade measures, which were deemed illegal by the U. Supreme Court last week, according to court documents.
  Feb 27, 2026 - $BLCO
• Bausch + Lomb (BLCO) Reports Record Q4 2025 Financial Results Driven by Strong Pharmaceutical and Vision Care Growth
  Bausch + Lomb Corporation (NYSE:BLCO) is one of the best Canadian stocks to buy under $20. On February 18, Bausch + Lomb reported record financial results for Q4 2025, with revenue rising 7% to $1.405 billion and adjusted EBITDA growing 27% to $330 million. This brought full-year revenue to $5.101 billion, driven by strong gains […]
  Feb 27, 2026 - $BLCO
• 5 Revealing Analyst Questions From Bausch + Lomb’s Q4 Earnings Call
  Bausch + Lomb’s fourth quarter showed strong revenue growth but fell short on non-GAAP profit expectations, prompting a modestly negative market reaction. Management attributed the performance to robust momentum in its dry eye portfolio, notably Miebo, and improved operating leverage through cost discipline. CEO Brenton Saunders emphasized the impact of executing their Vision 27 program, citing a shift toward higher-margin products and operational efficiency as key contributors. Saunders remarke
  Feb 25, 2026 - $BLCO
• Is It Time To Reassess Bausch + Lomb (BLCO) After Its Recent Share Price Strength?
  If you are wondering whether Bausch + Lomb is fairly priced or if there is still value on the table, this article will walk you through what the current share price might be telling you. The stock last closed at US$17.99, with returns of 5.6% over 7 days, 5.9% over 30 days, 8.5% year to date and 13.8% over the past year, which may have caught the attention of investors watching for shifts in risk and reward. Recent news coverage around Bausch + Lomb has focused on its position as a...
  Feb 24, 2026 - $BLCO
• Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®
  VAUGHAN, Ontario, February 24, 2026--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, announced today that Ophthalmology and Therapy published a new global narrative review examining the causes, burden and management of noninfectious conjunctival hyperemia (ocular redness). The review highlights the growing global prevalence of ocular redness driven by digital lifestyles, dry eye, contact lens wear, allergies a
  Feb 24, 2026 - $BLCO
• Separation Overhang Continues to Weigh on Bausch Health Companies Inc. (BHC) Outlook
  Bausch Health Companies Inc. (NYSE:BHC) is among the 7 Oversold Pharma Stocks to Buy Now. Bausch Health Companies Inc. (NYSE:BHC) is one of the most oversold stocks. TheFly reported on February 19 that Bank of America raised its price target for Bausch + Lomb (BLCO) to $15 from $13 and kept an Underperform rating. The […]
  Feb 23, 2026 - $BLCO
• 3 Small-Cap Stocks We Steer Clear Of
  Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
  Feb 23, 2026 - $BLCO
• Bausch Health Cos Q4 Earnings Call Highlights
  Bausch Health Cos (NYSE:BHC) executives said the company finished 2025 with its “eleventh consecutive quarter of growth” in revenue and adjusted EBITDA, as management highlighted broad-based commercial execution, improved balance sheet flexibility and a steady pipeline of business development activi
  Feb 19, 2026 - $BLCO